This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Large Multicenter Study

Steven G. Chrysant, MD, PhD; The Lisinopril-Hydrochlorothiazide Group

Arch Intern Med. 1994;154(7):737-743.

Abstract
Objective
To test the antihypertensive and metabolic effects of lisinopril, 10 mg/d (L); hydrochlorothiazide, 12.5 and 25 mg/d (H12.5 and H25); and its combination with lisinopril (L/H12.5 and L/H25) against placebo in patients with mild to moderate (stage I and stage II) hypertension.

Design
Multicenter, double-blind, placebo-controlled outpatient study of 12 weeks' duration.

Patients
After 4 weeks of single-blind placebo treatment, 505 patients whose sitting diastolic blood pressure was 100 to 114 mm Hg were randomized into the study—467 patients completed it (placebo, 71; L, 80; H12.5, 79; H25, 77; L/H12.5, 79; and L/H25, 81). The patients were seen in the clinic every 2 weeks, where measurements of their sitting and upright blood pressure and heart rate were taken 24±2 hours after drug administration. Complete blood cell counts with differential cell counts, blood chemistry studies, urinalyses, and electrocardiograms were done at baseline and during the study. Roentgenograms were done once at baseline.

Results
Compared with placebo, all drug regimens decreased sitting and upright blood pressure (P<.001) and had no effect on sitting and upright heart rate. The greatest effect was obtained with the combinations of L/H12.5 and L/H25. There was no difference between L/H12.5 and L/H25 or between H12.5 and H25. There were no serious clinical side effects except cough, which was slightly higher with L, L/H12.5, and L/H25. The only metabolic side effects were in serum potassium level, which was lower with H25 (P<.01), and serum glucose level, which was higher with H25 and L/H25 (P<.01).

Conclusions
The data suggest that (1) monotherapy of hypertension with L, H12.5, H25, L/H12.5, and L/H25 was effective and well tolerated; (2) the best results were achieved with L/H12.5 and L/H25; (3) lower doses of hydrochlorothiazide either alone or in combination with lisinopril were equipotent with higher doses and were free of metabolic side effects.

(Arch Intern Med. 1994;154:737-743)

Author Affiliations
From the Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma, Oklahoma City, and collaborating institutions. A complete listing of the collaborators is included in the acknowledgment.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacological and Clinical Profile of Moexipril: A Concise Review
Chrysant and Chrysant
J Clin Pharmacol 2004;44:827-836.
ABSTRACT | FULL TEXT  

The ALLHAT study: results and clinical implications
Chrysant
QJM 2003;96:771-773.
FULL TEXT  

Review: Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension
Motwani
Journal of Renin-Angiotensin-Aldosterone System 2002;3:72-78.
ABSTRACT  

Fixed Low-Dose Drug Combination for the Treatment of Hypertension
Chrysant
Arch Fam Med 1998;7:370-376.
ABSTRACT | FULL TEXT  

Newer Approaches to Antihypertensive Therapy: Use of Fixed-Dose Combination Therapy
Epstein and Bakris
Arch Intern Med 1996;156:1969-1978.
ABSTRACT  

Effects of Benazepril and Hydrochlorothiazide, Given Alone and in Low- and High-Dose Combinations, on Blood Pressure in Patients With Hypertension
Chrysant et al.
Arch Fam Med 1996;5:17-24.
ABSTRACT  

ACE INHIBITORS PLUS LOW-DOSE THIAZIDES FOR HYPERTENSION
JWatch General 1994;1994:1-1.
FULL TEXT